Browsing Artículos (Medicina) by Subject "Advanced breast cancer"
Now showing items 1-5 of 5
-
Article
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
(BMC, 2023)Background: We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and ...
-
Article
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
(Sage Journals, 2023)Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression free survival (PFS) compared ...
-
Article
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
(Elsevier, 2021)Background: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) ...
-
Article
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
(Elsevier, 2022)Background: Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in ...
-
Article
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving frst-line ribociclib plus fulvestrant
(Biomed Central LTD, 2023)Background The phase III MONALEESA-3 trial included frst- (1L) and second-line (2L) patients and demonstrated a signifcant ...